Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences' stock price has experienced significant fluctuations. As of late March 2026, the share price was approximately $2.70, with a market capitalization of around $11.49 million. Over the last 12 months, the stock price has decreased by approximately 55.13%, and by 74.01% over the last year, but saw an increase of 4.97% in the past month. Key events impacting the stock price include the FDA granting Rare Pediatric Disease Designation for iopofosine I 131 in October 2025, the company reporting its Third Quarter 2025 financial results and providing a corporate update in November 2025, outlining its 2026 priorities at the Biotech Showcase in January 2026, announcing the expansion of its global intellectual property estate in February 2026, and reporting its financial results for the year ended December 31, 2025, and providing corporate updates in March 2026.

As a clinical-stage biopharmaceutical company, Cellectar Biosciences' products are still in development, and therefore, traditional product demand seasonality is not yet applicable. Based on historical stock price data, February has shown the highest probability of positive returns for CLRB at 63.64%, while March has a 30.00% probability of a positive return.

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical and radiopharmaceutical company focused on discovering, developing, and commercializing drugs for cancer treatment. The company's core technology is its Phospholipid Drug Conjugate (PDC™) delivery platform, designed to selectively target tumor cells. The company's lead asset, Iopofosine I 131 (CLR 131), is being evaluated in Phase 2 clinical studies for various hematologic malignancies and pediatric high-grade gliomas. Other product candidates include CLR 125 (CLR 121125), an iodine-125 Auger-emitting program targeting solid tumors; CLR 225 (CLR 121225), an actinium-225 based alpha-emitting program targeting solid tumors; CLR 124, designed to detect tumors and metastases; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC.

Cellectar Biosciences, Inc. is headquartered in Florham Park, New Jersey, United States, and focuses on the discovery, development, and commercialization of drugs for cancer treatment in the United States. The company is also pursuing a Conditional Marketing Authorization (CMA) submission for iopofosine I 131 to the European Medicines Agency (EMA) in Q3 2026, targeting potential European commercialization in early 2027.

Cellectar Biosciences' brand reputation has been influenced by positive clinical and regulatory advancements, as well as ongoing financial challenges. Positive events include strong clinical data for Iopofosine I 131, FDA Breakthrough Therapy Designation, Rare Pediatric Disease Designation, EMA PRIME Designation, promising preclinical data for CLR 225, and strategic supply agreements. Challenges to its reputation include financial sustainability and funding risks, zero revenue, and stock price decline.

Cellectar Biosciences (CLRB) stock ownership is distributed among institutional shareholders, insiders, and retail investors. Approximately 8.18% to 16.41% of the stock is owned by institutional shareholders, insiders hold around 0.73% to 79.20% of the stock, while retail investors own approximately 12.62% to 90.98%. Major institutional owners include Bleichroeder LP, Vanguard Group Inc., and BlackRock, Inc. The largest individual shareholder is Austin W. Greenhouse David M. Marxe, owning 1.14 million shares, representing 26.94% of the company.